Beam Therapeutics (BEAM) Operating Margin (2019 - 2026)
Beam Therapeutics (BEAM) reported Operating Margin of 337.81% for Q1 2026, up 125905.0% year-over-year from N/an in Q1 2025, and down 2109.66% quarter-over-quarter from 15.29% in Q4 2025.
Beam Therapeutics (BEAM) Operating Margin (2019 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has 8 years of Operating Margin data on file, last reported at 337.81% in Q1 2026.
- Operating Margin for Q1 2026 came in at 337.81%, up 125905.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 226.58% (up 45089.0% YoY), and the FY2025 annual result was 274.57%, up 37968.0% from the prior year.
- Operating Margin eased to 337.81% in Q1 2026 per BEAM's latest filing, from 15.29% in the prior quarter.
- Over five years, Operating Margin peaked at 42.02% in Q4 2023 and troughed at 1596.87% in Q1 2025.
- A 5-year average of 704.39% and a median of 577.9% in 2022 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2022 and 2024: Operating Margin surged 333864600 bps in 2022, then sank 99663 bps in 2024.
- A 5-year view of Operating Margin shows it stood at 444.1% in 2022, then jumped by 109 bps to 42.02% in 2023, then sank by 892 bps to 332.71% in 2024, then soared by 95 bps to 15.29% in 2025, then sank by 2110 bps to 337.81% in 2026.
- Business Quant data shows BEAM's Operating Margin at 337.81% in Q1 2026, 15.29% in Q4 2025, and 1307.6% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Beam Therapeutics | 3.53 Bn | 3.53 Bn | - | -337.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -337.81% |
| Dec 31, 2025 | -15.29% |
| Sep 30, 2025 | -1,307.60% |
| Jun 30, 2025 | -1,419.22% |
| Mar 31, 2025 | -1,596.87% |
| Dec 31, 2024 | -332.71% |
| Sep 30, 2024 | -746.40% |
| Jun 30, 2024 | -891.06% |
| Mar 31, 2024 | -1,405.29% |
| Dec 31, 2023 | 42.02% |
| Sep 30, 2023 | -629.72% |
| Jun 30, 2023 | -507.79% |
| Mar 31, 2023 | -408.66% |
| Dec 31, 2022 | -444.10% |
| Sep 30, 2022 | -577.90% |
| Jun 30, 2022 | -492.23% |
| Mar 31, 2022 | -904.00% |
| Dec 31, 2021 | -124.31% |
| Sep 30, 2021 | -9,126.34% |
| Jun 30, 2021 | -982,900.00% |